Business Context and Reporting Period
Karyopharm Therapeutics Inc. (KPTI) filed a Form 8-K on September 16, 2024, regarding a listing deficiency notice received from the Nasdaq Stock Market. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on the status of the company's stock listing.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq. The company's common stock bid price closed below the minimum $1.00 per share requirement for 32 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). This filing does not report changes in operational performance or financial position compared to prior periods.
Outlook, Risks, and Contingencies
- Compliance Period: The company has an initial 180-day compliance period ending March 17, 2025, to regain compliance.
- Compliance Requirement: To cure the deficiency, the stock must close at $1.00 or more for 10 consecutive business days before the compliance date.
- Contingency Plans: If compliance is not met by March 17, 2025, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market and meets specific market value requirements. This may involve a reverse stock split.
- Delisting Risk: If the company fails to regain compliance during the additional period or is deemed ineligible, Nasdaq may initiate delisting proceedings. The company may appeal such a determination, but success is not assured.
- Management Intent: Management intends to monitor the bid price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of KPTI stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or transfer to the Nasdaq Capital Market.
- Track the 10-day consecutive closing price requirement to determine if the initial compliance period is satisfied.
- Review the company's market value of publicly held shares to assess eligibility for the Nasdaq Capital Market transfer.